MURRAY HILL, N.J.--(BUSINESS WIRE)--Aug. 20, 2008--C. R. Bard,
Inc. (NYSE: BCR) today announced the publication of the North American
Silver-Coated Endotracheal Tube (NASCENT) clinical study results in
the August 20, 2008 edition of the Journal of the American Medical
Association (JAMA). The NASCENT study - which enrolled 2,003 patients
in 54 hospitals - evaluated the efficacy of the Agento(R) I.C.
silver-coated endotracheal tube (ETT) in the reduction of
microbiologically confirmed ventilator-associated pneumonia (VAP). The
U.S. Food and Drug Administration cleared the Agento(R) I.C.
silver-coated ETT in November 2007 for the prevention of VAP in
patients intubated for 24 hours or longer. As reported in JAMA, the
NASCENT study demonstrated that the Agento(R) I.C. silver-coated ETT
reduced the incidence of VAP by 36% in the overall study population,
with a 48% reduction in the first 10 days of intubation.
VAP is one of the most costly hospital acquired infections and is
associated with high patient mortality and morbidity. It is especially
prevalent in hospital intensive care units where a ventilated patient
typically has an ETT in place for more than 24 hours. The Agento(R)
I.C. silver-coated ETT incorporates Bard's proprietary polymer
technology which allows a coated ETT to elute silver ions to kill the
microorganisms responsible for VAP. The device is marketed by the Bard
Medical Division, located in Covington, Georgia.
While hospitals and other health care facilities have implemented
a number of prevention methods to decrease the risk of VAP, they all
require significant nursing intervention and consistent application to
be efficacious. Marin Kollef, M.D., principal investigator of the
NASCENT study said, "This study marks a very important milestone for
the prevention of VAP in hospitals. One of the major benefits of the
Agento(R) I.C. silver-coated endotracheal tube is that it is the first
prevention option available that requires no further action after
placement by the healthcare provider."
Bard Chairman and Chief Executive Officer, Timothy M. Ring
commented, "In developing the Agento(R) I.C. silver-coated
endotracheal tube, Bard sponsored the largest randomized controlled
trial in the field of VAP prevention and we are pleased that the
efforts of the independent clinical investigators have been recognized
by such a renowned scientific journal. Publication in JAMA reflects
the quality of their study and significance of their results. We look
forward to the benefits that the Agento(R) I.C. silver-coated
endotracheal tube can provide hospitals and clinicians in their
efforts to reduce the incidence of VAP and improve patients' lives."
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology and surgical specialty products.
This press release may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995,
which are based on management's current expectations, the accuracy of
which is necessarily subject to risks and uncertainties. These
statements are not historical in nature and use words such as
"anticipate", "estimate", "expect", "project", "intend", "forecast",
"plan", "believe", and other words of similar meaning in connection
with any discussion of future operating or financial performance. Many
factors may cause actual results to differ materially from anticipated
results including product developments, sales efforts, income tax
matters, the outcomes of contingencies such as legal proceedings, and
other economic, business, competitive and regulatory factors. The
company undertakes no obligation to update its forward-looking
statements. Please refer to the Cautionary Statement Regarding
Forward-Looking Information in our June 30, 2008 Form 10-Q for more
detailed information about these and other factors that may cause
actual results to differ materially from those expressed or implied.
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908-277-8413
Vice President, Investor Relations
Holly P. Glass, 908-277-8117
Vice President, Government and Public Relations
SOURCE: C. R. Bard, Inc.